Results 1 to 10 of about 31,394 (214)
Acta Biochimica et Biophysica Sinica, 2023 Intervertebral disc degeneration is mainly caused by irregular matrix metabolism in nucleus pulposus cells and involves inflammatory factors such as TNF-α.
Chen Weijian +9 more
doaj +2 more sources
Rosuvastatin attenuates tubulointerstitial fibrosis by targeting the HOXA13 USAG1 BMP7 pathway [PDF]
Scientific ReportsStatins act as antifibrotic agents but their mechanism is unclear. Therefore, we aimed to evaluate the antifibrotic effects of rosuvastatin in a chronic kidney fibrosis model in vivo and transforming growth factor-β1 (TGF-β1)-stimulated Madin-Darby ...
Donghwan Oh +8 more
doaj +2 more sources
Journal of Hepatology, 2019 BACKGROUND NGM282, an engineered analogue of the gut hormone FGF19, improves hepatic steatosis and fibrosis biomarkers in patients with non-alcoholic steatohepatitis (NASH).
Stephen Harrison, Margery Connelly
exaly +2 more sources
Rosuvastatin protects against oxLDL-induced endothelial cell oxidative stress and attenuates atherosclerotic plaque formation in ApoE-/- mice through the NF-κB pathway. [PDF]
PLoS ONECardiovascular disease is one of the diseases with the highest global incidence and mortality rates, and atherosclerosis is its basic cause. Endothelial dysfunction induced by risk factors such as lipid oxidation or inflammatory stimulation is a critical
Yichen Wu +6 more
doaj +2 more sources
British medical journal, 2023 Objective To compare the long term efficacy and safety of rosuvastatin with atorvastatin treatment in adults with coronary artery disease. Design Randomised, open label, multicentre trial.
Yong-Joon Lee +15 more
semanticscholar +1 more source
Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin
Clinical pharmacology and therapy, 2023 Ticagrelor and rosuvastatin are often used concomitantly after atherothrombotic events. Several cases of rhabdomyolysis during concomitant ticagrelor and rosuvastatin have been reported, suggesting a drug–drug interaction.
Minna Lehtisalo +9 more
semanticscholar +1 more source
British Journal of Clinical Pharmacology, 2023 We present 3 patients diagnosed with rhabdomyolysis 1–6 months after the initiation of concomitant rosuvastatin and ticagrelor medication. A literature review and Food and Drug Administration adverse event reporting system revealed >40 reports of ...
Minna Lehtisalo +8 more
semanticscholar +1 more source
Rosuvastatin Treatment Affects Both Basal and Glucose-Induced Insulin Secretion in INS-1 832/13 Cells. [PDF]
PLoS ONE, 2016 Rosuvastatin is a member of the statin family. Like the other statins it is prescribed to lower cholesterol levels and thereby reduce the risk of cardiovascular events.
Vishal A Salunkhe +3 more
doaj +1 more source
PLoS ONE, 2021 Some studies have suggested the antihypertensive effects of statins, a class of lipid-lowering agents, particularly in patients with hypertension. However, the evidence for the role of statins in blood pressure (BP) lowering is controversial, and no meta-
Sungjae Lee +2 more
doaj +1 more source